What is the statistical relationship between prostate cancer and bladder cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Statistical Relationship Between Prostate Cancer and Bladder Cancer

Men with prostate cancer have a significantly elevated risk of developing bladder cancer, with studies showing a 3-4 fold increased incidence compared to the general population, and this relationship appears bidirectional.

Magnitude of the Association

The statistical relationship between these two malignancies is substantial and well-documented:

  • Prostate cancer patients developing bladder cancer: Men diagnosed with prostate cancer have approximately 4.3 times higher risk (SIR 4.31,95% CI 2.41-7.11) of subsequently developing bladder cancer compared to age-matched controls 1

  • Bladder cancer patients developing prostate cancer: Conversely, men with bladder cancer have approximately 3.8 times higher risk (SIR 3.83,95% CI 1.91-6.86) of developing prostate cancer 1

  • Overall incidence: In clinical practice, approximately 1.5-3.8% of prostate cancer patients will develop bladder cancer, while 17-25% of bladder cancer patients will have concurrent or subsequent prostate cancer 2, 3

Recent Mendelian randomization analysis confirms causality, demonstrating that genetically predicted prostate cancer increases bladder cancer risk (OR 1.22,95% CI 1.13-1.31 in FinnGen; OR 1.13,95% CI 1.05-1.22 in PRACTICAL database) 4.

Treatment-Related Risk Factors

Radiation therapy substantially increases bladder cancer risk beyond the baseline association:

  • External beam radiation therapy (EBRT): Hazard ratio of 1.72 for bladder cancer development and 2.39 for bladder cancer death compared to radical prostatectomy 5

  • Brachytherapy: Similar risk elevation with HR 1.85 for bladder cancer diagnosis and 2.57 for bladder cancer death 5

  • Combined EBRT + brachytherapy: Highest risk with HR 1.80 for diagnosis and 3.02 for death 5

  • Smoking amplifies radiation risk: Smokers treated with radiation have nearly 4-fold increased risk (HR 3.65,95% CI 1.45-9.16) of bladder cancer 3

Importantly, radical prostatectomy patients have approximately half the risk of developing bladder cancer compared to radiation-treated patients (HR 0.51,95% CI 0.29-0.89) 3.

Clinical Characteristics of Radiation-Associated Bladder Cancer

Bladder cancers occurring after prostate radiation are more aggressive:

  • Higher proportion of muscle-invasive disease (≥T2 stage) at presentation
  • Increased frequency of ≥T3 disease (extravesical extension)
  • More likely to be sarcomatoid variant histology
  • All differences statistically significant (p < 0.01) 5

Surveillance Implications

Based on the American Cancer Society prostate cancer survivorship guidelines 6:

For prostate cancer survivors with hematuria:

  • Perform thorough evaluation to rule out bladder cancer
  • Refer to urology for cystoscopy
  • Do not screen asymptomatic survivors with routine urinalysis

For radiation-treated patients:

  • Maintain heightened clinical suspicion for bladder cancer
  • Adhere to standard colorectal cancer screening (radiation also increases rectal cancer risk)
  • Evaluate any new rectal bleeding or persistent urinary symptoms promptly
  • Consider multidisciplinary evaluation including the treating radiation oncologist

Common Pitfalls to Avoid

  1. Diagnostic bias: Approximately 12-28% of "coincident" cancers represent diagnostic bias (incidental findings during workup for the other cancer). After correcting for this, the true association remains highly significant 2

  2. Underestimating radiation latency: The increased bladder cancer risk from radiation persists long-term, requiring vigilance beyond 5-10 years post-treatment

  3. Ignoring smoking status: Smoking is an independent risk factor that synergizes with radiation exposure—aggressive smoking cessation counseling is essential

  4. Assuming testosterone is the link: Despite biological plausibility, Mendelian randomization studies found no causal relationship between testosterone levels and bladder cancer risk (P > 0.05) 4, suggesting other mechanisms drive this association

Mechanistic Considerations

The bidirectional relationship suggests:

  • Shared risk factors: Smoking, age, occupational exposures affect both cancers
  • Field cancerization: Common carcinogenic pathways affecting the entire genitourinary tract
  • Radiation-induced carcinogenesis: Direct DNA damage in bladder tissue from prostate radiation
  • Surveillance bias: More intensive monitoring of prostate cancer patients may detect bladder cancers earlier (though this doesn't fully explain the magnitude of association)

References

2
Research

Coincidence of bladder and prostate cancer.

The Journal of urology, 1997

6
Guideline

american cancer society prostate cancer survivorship care guidelines.

Ca-A Cancer Journal for Clinicians, 2014

Related Questions

In a 76-year-old patient with a history of prostate cancer who presented after a syncopal episode and whose head and neck computed tomography angiography shows stenosis of the anterior cerebral artery (ACA), posterior cerebral artery (PCA), and middle cerebral artery (MCA) M2 branch with bilateral putamen infarcts, what is the next step in management?
What antidepressant is recommended for a patient who has completed prostate cancer treatment and is experiencing sexual side effects, excluding mirtazapine and bupropion?
Are prostate cancers typically round in shape?
In a prostate MRI, a 10‑mm well‑defined T2‑hypointense lesion in the left peripheral zone at the base shows moderate diffusion restriction and early contrast enhancement. What is the likelihood that this lesion represents clinically significant prostate cancer?
What is the recommended management for a patient with Gleason 3 + 4 (score 7) prostate cancer and a PSA of 4 ng/mL?
Can dextromethorphan be safely used as a cough suppressant in patients with mild asthma?
How accurate is the basal metabolic rate calculation from an InBody scan (bioelectrical impedance analysis)?
What over-the-counter options can be used to lower high uric acid levels?
How should a neonate with a hemodynamically significant patent ductus arteriosus (PDA) causing wide pulse pressure, who is in septic shock and has persistent pulmonary hypertension of the newborn (PPHN), be treated?
What does an alpha‑gal (galactose-α-1,3-galactose) specific IgE level of 0.14 kU/L indicate?
Is hydrochlorothiazide (HCTZ) a potassium-sparing diuretic?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.